PubMed:26582603
Annnotations
Glycan-Motif
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-10 | https://glytoucan.org/Structures/Glycans/G00017MO | denotes | Hyaluronan |
| T2 | 693-703 | https://glytoucan.org/Structures/Glycans/G00017MO | denotes | Hyaluronan |
GlyCosmos6-Glycan-Motif-Image
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 0-10 | Glycan_Motif | denotes | Hyaluronan | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
| T2 | 693-703 | Glycan_Motif | denotes | Hyaluronan | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00017MO |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-93 | Sentence | denotes | Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. |
| TextSentencer_T2 | 94-317 | Sentence | denotes | Chronic myeloid leukemia is a myeloproliferative syndrome characterized by the presence of the Philadelphia chromosome (Ph), generated by a reciprocal translocation occurring between chromosomes 9 and 22 [t(9;22)(q34;q11)]. |
| TextSentencer_T3 | 318-413 | Sentence | denotes | As a consequence, a fusion gene (bcr-abl) encoding a constitutively active kinase is generated. |
| TextSentencer_T4 | 414-512 | Sentence | denotes | The first-line treatment consists on BCR-ABL inhibitors such as Imatinib, Nilotinib and Dasatinib. |
| TextSentencer_T5 | 513-587 | Sentence | denotes | Nevertheless, such treatment may lead to the selection of resistant cells. |
| TextSentencer_T6 | 588-692 | Sentence | denotes | Therefore, finding molecules that enhance the anti-proliferative effect of first-line drugs is of value. |
| TextSentencer_T7 | 693-790 | Sentence | denotes | Hyaluronan oligomers (oHA) are known to be able to sensitize several tumor cells to chemotherapy. |
| TextSentencer_T8 | 791-914 | Sentence | denotes | We have previously demonstrated that oHA can revert Vincristine resistance in mouse lymphoma and human leukemia cell lines. |
| TextSentencer_T9 | 915-992 | Sentence | denotes | However, little is known about the role of oHA in hematological malignancies. |
| TextSentencer_T10 | 993-1151 | Sentence | denotes | The aim of this work was to determine whether oHA are able to modulate the anti-proliferative effect of Imatinib in chronic myeloid leukemia (CML) cell lines. |
| TextSentencer_T11 | 1152-1260 | Sentence | denotes | The effect on apoptosis and senescence as well as the involvement of signaling pathways were also evaluated. |
| TextSentencer_T12 | 1261-1341 | Sentence | denotes | For this purpose, the human CML cell lines K562 and Kv562 (resistant) were used. |
| TextSentencer_T13 | 1342-1475 | Sentence | denotes | We demonstrated that oHA sensitized both cell lines to the anti-proliferative effect of Imatinib increasing apoptosis and senescence. |
| TextSentencer_T14 | 1476-1578 | Sentence | denotes | Moreover, this effect would be accomplished through the down-regulation of the PI3K signaling pathway. |
| TextSentencer_T15 | 1579-1689 | Sentence | denotes | These findings highlight the potential of oHA when used as a co-adjuvant therapy for chronic myeloid leukemia. |
| T1 | 0-93 | Sentence | denotes | Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. |
| T2 | 94-317 | Sentence | denotes | Chronic myeloid leukemia is a myeloproliferative syndrome characterized by the presence of the Philadelphia chromosome (Ph), generated by a reciprocal translocation occurring between chromosomes 9 and 22 [t(9;22)(q34;q11)]. |
| T3 | 318-413 | Sentence | denotes | As a consequence, a fusion gene (bcr-abl) encoding a constitutively active kinase is generated. |
| T4 | 414-587 | Sentence | denotes | The first-line treatment consists on BCR-ABL inhibitors such as Imatinib, Nilotinib and Dasatinib. Nevertheless, such treatment may lead to the selection of resistant cells. |
| T5 | 588-692 | Sentence | denotes | Therefore, finding molecules that enhance the anti-proliferative effect of first-line drugs is of value. |
| T6 | 693-790 | Sentence | denotes | Hyaluronan oligomers (oHA) are known to be able to sensitize several tumor cells to chemotherapy. |
| T7 | 791-914 | Sentence | denotes | We have previously demonstrated that oHA can revert Vincristine resistance in mouse lymphoma and human leukemia cell lines. |
| T8 | 915-992 | Sentence | denotes | However, little is known about the role of oHA in hematological malignancies. |
| T9 | 993-1151 | Sentence | denotes | The aim of this work was to determine whether oHA are able to modulate the anti-proliferative effect of Imatinib in chronic myeloid leukemia (CML) cell lines. |
| T10 | 1152-1260 | Sentence | denotes | The effect on apoptosis and senescence as well as the involvement of signaling pathways were also evaluated. |
| T11 | 1261-1341 | Sentence | denotes | For this purpose, the human CML cell lines K562 and Kv562 (resistant) were used. |
| T12 | 1342-1475 | Sentence | denotes | We demonstrated that oHA sensitized both cell lines to the anti-proliferative effect of Imatinib increasing apoptosis and senescence. |
| T13 | 1476-1578 | Sentence | denotes | Moreover, this effect would be accomplished through the down-regulation of the PI3K signaling pathway. |
| T14 | 1579-1689 | Sentence | denotes | These findings highlight the potential of oHA when used as a co-adjuvant therapy for chronic myeloid leukemia. |
| T1 | 0-93 | Sentence | denotes | Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. |
| T2 | 94-317 | Sentence | denotes | Chronic myeloid leukemia is a myeloproliferative syndrome characterized by the presence of the Philadelphia chromosome (Ph), generated by a reciprocal translocation occurring between chromosomes 9 and 22 [t(9;22)(q34;q11)]. |
| T3 | 318-413 | Sentence | denotes | As a consequence, a fusion gene (bcr-abl) encoding a constitutively active kinase is generated. |
| T4 | 414-512 | Sentence | denotes | The first-line treatment consists on BCR-ABL inhibitors such as Imatinib, Nilotinib and Dasatinib. |
| T5 | 513-587 | Sentence | denotes | Nevertheless, such treatment may lead to the selection of resistant cells. |
| T6 | 588-692 | Sentence | denotes | Therefore, finding molecules that enhance the anti-proliferative effect of first-line drugs is of value. |
| T7 | 693-790 | Sentence | denotes | Hyaluronan oligomers (oHA) are known to be able to sensitize several tumor cells to chemotherapy. |
| T8 | 791-914 | Sentence | denotes | We have previously demonstrated that oHA can revert Vincristine resistance in mouse lymphoma and human leukemia cell lines. |
| T9 | 915-992 | Sentence | denotes | However, little is known about the role of oHA in hematological malignancies. |
| T10 | 993-1151 | Sentence | denotes | The aim of this work was to determine whether oHA are able to modulate the anti-proliferative effect of Imatinib in chronic myeloid leukemia (CML) cell lines. |
| T11 | 1152-1260 | Sentence | denotes | The effect on apoptosis and senescence as well as the involvement of signaling pathways were also evaluated. |
| T12 | 1261-1341 | Sentence | denotes | For this purpose, the human CML cell lines K562 and Kv562 (resistant) were used. |
| T13 | 1342-1475 | Sentence | denotes | We demonstrated that oHA sensitized both cell lines to the anti-proliferative effect of Imatinib increasing apoptosis and senescence. |
| T14 | 1476-1578 | Sentence | denotes | Moreover, this effect would be accomplished through the down-regulation of the PI3K signaling pathway. |
| T15 | 1579-1689 | Sentence | denotes | These findings highlight the potential of oHA when used as a co-adjuvant therapy for chronic myeloid leukemia. |
GlyCosmos6-Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-10 | https://glytoucan.org/Structures/Glycans/G00017MO | denotes | Hyaluronan |
| T2 | 693-703 | https://glytoucan.org/Structures/Glycans/G00017MO | denotes | Hyaluronan |
GlycoBiology-FMA
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| _T1 | 0-10 | FMAID:167396 | denotes | Hyaluronan |
| _T2 | 0-10 | FMAID:63014 | denotes | Hyaluronan |
| _T3 | 202-212 | FMAID:67093 | denotes | chromosome |
| _T4 | 202-212 | FMAID:197979 | denotes | chromosome |
| _T5 | 202-212 | FMAID:84056 | denotes | chromosome |
| _T6 | 202-212 | FMAID:226764 | denotes | chromosome |
| _T7 | 202-212 | FMAID:165175 | denotes | chromosome |
| _T8 | 202-212 | FMAID:84055 | denotes | chromosome |
| _T9 | 202-212 | FMAID:197978 | denotes | chromosome |
| _T10 | 277-288 | FMAID:67093 | denotes | chromosomes |
| _T11 | 277-288 | FMAID:84055 | denotes | chromosomes |
| _T12 | 277-288 | FMAID:226764 | denotes | chromosomes |
| _T13 | 277-288 | FMAID:84056 | denotes | chromosomes |
| _T14 | 277-288 | FMAID:197978 | denotes | chromosomes |
| _T15 | 277-288 | FMAID:165175 | denotes | chromosomes |
| _T16 | 277-288 | FMAID:197979 | denotes | chromosomes |
| _T17 | 345-349 | FMAID:198663 | denotes | gene |
| _T18 | 581-586 | FMAID:169002 | denotes | cells |
| _T19 | 581-586 | FMAID:68646 | denotes | cells |
| _T20 | 693-703 | FMAID:63014 | denotes | Hyaluronan |
| _T21 | 693-703 | FMAID:167396 | denotes | Hyaluronan |
| _T22 | 768-773 | FMAID:169002 | denotes | cells |
| _T23 | 768-773 | FMAID:68646 | denotes | cells |
uniprot-human
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 451-454 | http://www.uniprot.org/uniprot/P11274 | denotes | BCR |
| T2 | 455-458 | http://www.uniprot.org/uniprot/P00519 | denotes | ABL |
uniprot-mouse
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 351-354 | http://www.uniprot.org/uniprot/Q6PAJ1 | denotes | bcr |
| T2 | 355-358 | http://www.uniprot.org/uniprot/Q61258 | denotes | abl |
GlycoBiology-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 189-201 | http://purl.bioontology.org/ontology/NCBITAXON/23113 | denotes | Philadelphia |
| T2 | 581-586 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
| T3 | 599-606 | http://purl.bioontology.org/ontology/STY/T033 | denotes | finding |
| T4 | 768-773 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
| T5 | 1585-1593 | http://purl.bioontology.org/ontology/STY/T033 | denotes | findings |
| T6 | 1640-1642 | http://purl.bioontology.org/ontology/NCBITAXON/13893 | denotes | co |
GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 21-30 | http://purl.obolibrary.org/obo/GO_0046960 | denotes | sensitize |
| T2 | 744-753 | http://purl.obolibrary.org/obo/GO_0046960 | denotes | sensitize |
| T3 | 1367-1377 | http://purl.obolibrary.org/obo/GO_0046960 | denotes | sensitized |
| T4 | 386-399 | http://purl.obolibrary.org/obo/GO_0033674 | denotes | active kinase |
| T5 | 386-399 | http://purl.obolibrary.org/obo/GO_0016301 | denotes | active kinase |
| T6 | 1166-1175 | http://purl.obolibrary.org/obo/GO_0006915 | denotes | apoptosis |
| T7 | 1166-1175 | http://purl.obolibrary.org/obo/GO_0097194 | denotes | apoptosis |
| T8 | 1450-1459 | http://purl.obolibrary.org/obo/GO_0006915 | denotes | apoptosis |
| T9 | 1450-1459 | http://purl.obolibrary.org/obo/GO_0097194 | denotes | apoptosis |
| T10 | 1221-1230 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
| T11 | 1560-1569 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
| T12 | 1221-1239 | http://purl.obolibrary.org/obo/GO_0007165 | denotes | signaling pathways |
| T13 | 1560-1577 | http://purl.obolibrary.org/obo/GO_0007165 | denotes | signaling pathway |
| T14 | 1537-1547 | http://purl.obolibrary.org/obo/GO_0065007 | denotes | regulation |
| T15 | 1555-1559 | http://purl.obolibrary.org/obo/GO_0016303 | denotes | PI3K |
| T16 | 1555-1569 | http://purl.obolibrary.org/obo/GO_0014065 | denotes | PI3K signaling |
GO-CC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 56-60 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T2 | 903-907 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T3 | 1140-1144 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T4 | 1293-1297 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T5 | 581-586 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T6 | 768-773 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T7 | 202-212 | http://purl.obolibrary.org/obo/GO_0005694 | denotes | chromosome |
| T8 | 277-288 | http://purl.obolibrary.org/obo/GO_0005694 | denotes | chromosomes |
Lectin
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| Lectin_T1 | 355-358 | https://acgg.asia/db/lfdb/LfDB0126 | denotes | abl |
| Lectin_T2 | 455-458 | https://acgg.asia/db/lfdb/LfDB0126 | denotes | ABL |
| Lectin_T3 | 1135-1138 | https://acgg.asia/db/lfdb/LfDB0130 | denotes | CML |
| Lectin_T4 | 1289-1292 | https://acgg.asia/db/lfdb/LfDB0130 | denotes | CML |
| Lectin_T5 | 1135-1138 | https://acgg.asia/db/lfdb/LfDB0349 | denotes | CML |
| Lectin_T6 | 1289-1292 | https://acgg.asia/db/lfdb/LfDB0349 | denotes | CML |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 31-55 | Disease | denotes | chronic myeloid leukemia | http://purl.obolibrary.org/obo/MONDO_0011996 |
| T2 | 94-118 | Disease | denotes | Chronic myeloid leukemia | http://purl.obolibrary.org/obo/MONDO_0011996 |
| T3 | 455-458 | Disease | denotes | ABL | http://purl.obolibrary.org/obo/MONDO_0008692 |
| T4 | 762-767 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
| T5 | 875-883 | Disease | denotes | lymphoma | http://purl.obolibrary.org/obo/MONDO_0005062 |
| T6 | 894-902 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
| T7 | 965-991 | Disease | denotes | hematological malignancies | http://purl.obolibrary.org/obo/MONDO_0002334|http://purl.obolibrary.org/obo/MONDO_0044881 |
| T9 | 1109-1133 | Disease | denotes | chronic myeloid leukemia | http://purl.obolibrary.org/obo/MONDO_0011996 |
| T10 | 1135-1138 | Disease | denotes | CML | http://purl.obolibrary.org/obo/MONDO_0001014|http://purl.obolibrary.org/obo/MONDO_0011996 |
| T12 | 1289-1292 | Disease | denotes | CML | http://purl.obolibrary.org/obo/MONDO_0001014|http://purl.obolibrary.org/obo/MONDO_0011996 |
| T14 | 1664-1688 | Disease | denotes | chronic myeloid leukemia | http://purl.obolibrary.org/obo/MONDO_0011996 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 31-55 | Phenotype | denotes | chronic myeloid leukemia | HP:0005506 |
| T2 | 94-118 | Phenotype | denotes | Chronic myeloid leukemia | HP:0005506 |
| T3 | 762-767 | Phenotype | denotes | tumor | HP:0002664 |
| T4 | 875-883 | Phenotype | denotes | lymphoma | HP:0002665 |
| T5 | 894-902 | Phenotype | denotes | leukemia | HP:0001909 |
| T6 | 1109-1133 | Phenotype | denotes | chronic myeloid leukemia | HP:0005506 |
| T7 | 1135-1138 | Phenotype | denotes | CML | HP:0005506 |
| T8 | 1289-1292 | Phenotype | denotes | CML | HP:0005506 |
| T9 | 1664-1688 | Phenotype | denotes | chronic myeloid leukemia | HP:0005506 |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 869-874 | OrganismTaxon | denotes | mouse | 10088|10090 |
| T3 | 888-893 | OrganismTaxon | denotes | human | 9606 |
| T4 | 1283-1288 | OrganismTaxon | denotes | human | 9606 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 202-212 | Body_part | denotes | chromosome | http://purl.obolibrary.org/obo/GO_0005694 |
| T2 | 277-288 | Body_part | denotes | chromosomes | http://purl.obolibrary.org/obo/GO_0005694 |
CL-cell
| Id | Subject | Object | Predicate | Lexical cue | cl_id |
|---|---|---|---|---|---|
| T1 | 762-773 | Cell | denotes | tumor cells | http://purl.obolibrary.org/obo/CL:0001063 |